Vaxcyte grants CMO RSUs, options on 140K shares
Vaxcyte granted its Chief Medical Officer a sizable mix of RSUs and stock options with time-based vesting tied to continued service.
Rhea-AI Filing Summary
Vaxcyte, Inc. (PCVX) reported that Chief Medical Officer Luis Jodar received new equity awards on September 4, 2026. He was granted 52,632 restricted stock units, each representing one share of common stock, and a stock option for 88,254 shares at an exercise price of $61.16 per share, expiring September 4, 2036. The RSUs vest 25% on September 7, 2027 and 12.5% every six months thereafter, and the option vests 25% on August 31, 2027 and monthly thereafter, in each case subject to his continued service. No Rule 10b5-1 trading plan is reported.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 140,886 shares
Grant/Award
2 txns
Insider
Jodar Luis
Role
Chief Medical Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) F2 | 88,254 | $0.00 | $0.00 |
| Grant/Award | Common Stock F1 | 52,632 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (right to buy) — 88,254 contracts (Direct);
Common Stock — 52,632 shares (Direct)
Footnotes (2)
- F1. Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs vest as to 1/4 of the shares subject to the award on September 7, 2027 and 1/8 of the shares every six months thereafter, subject to Reporting Person's continuous service with the Issuer through each such date.
- F2. 1/4 of the shares subject to the option shall vest on August 31, 2027, and 1/48 of the shares shall vest monthly thereafter, subject to Reporting Person's continuous service with the Issuer through each such date.
Key Figures
RSUs granted: 52,632 units
Option shares granted: 88,254 shares
Option exercise price: $61.16 per share
+3 more
6 metrics
RSUs granted
52,632 units
Restricted stock units granted to Chief Medical Officer on September 4, 2026
Option shares granted
88,254 shares
Shares underlying stock option granted on September 4, 2026
Option exercise price
$61.16 per share
Exercise price for the stock option granted to the Chief Medical Officer
Option expiration date
September 4, 2036
Expiration of stock option covering 88,254 shares
Initial RSU vesting date
September 7, 2027
25% of RSU shares vest on this date, subject to continued service
Initial option vesting date
August 31, 2027
25% of option shares vest on this date, subject to continued service
Key Terms
restricted stock units ("RSUs"), contingent right, vest
3 terms
restricted stock units ("RSUs") financial
"Represents the number of shares of Common Stock underlying restricted stock units ("RSUs")."
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
contingent right financial
"Each RSU represents the contingent right to receive one share"
vest financial
"The RSUs vest as to 1/4 of the shares subject to the award"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
FAQ
What equity awards did Vaxcyte (PCVX) grant to its Chief Medical Officer?
On September 4, 2026, Vaxcyte granted Chief Medical Officer Luis Jodar 52,632 restricted stock units and a stock option covering 88,254 shares of common stock at an exercise price of $61.16 per share, as part of his equity compensation.
How do the new RSUs for Vaxcyte (PCVX) Chief Medical Officer vest?
The 52,632 RSUs granted to Chief Medical Officer Luis Jodar vest as follows: 25% of the shares on September 7, 2027 and 12.5% of the shares every six months thereafter, subject to his continuous service with Vaxcyte.
What is the vesting schedule of the new Vaxcyte (PCVX) stock option?
The stock option for 88,254 shares vests as follows: 25% of the shares on August 31, 2027, and 1/48 of the shares monthly thereafter, provided Chief Medical Officer Luis Jodar continues his service with Vaxcyte through each vesting date.
What is the exercise price and expiration date of the new Vaxcyte (PCVX) option?
Chief Medical Officer Luis Jodar’s new option has an exercise price of $61.16 per share and expires on September 4, 2036, giving him the right to purchase up to 88,254 shares of Vaxcyte common stock before that date, subject to vesting.
Were the Vaxcyte (PCVX) equity awards to the Chief Medical Officer made under a Rule 10b5-1 plan?
No. The filing states that no Rule 10b5-1 trading plan is reported in connection with the September 4, 2026 equity awards to Chief Medical Officer Luis Jodar.
AI-generated analysis. How Rhea-AI works. Not financial advice.
